• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, October 23, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Study shows that African eye worm threatens elimination of river blindness

Bioengineer by Bioengineer
November 20, 2019
in Health
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Efforts to eliminate river blindness, a debilitating disease affecting millions in Africa, will be hampered by another parasitic infection known as Loiasis, or ‘African eye worm,’ study published in Clinical Infectious Diseases says

IMAGE

Credit: Photo credit: Neil Brandvold-DNDi

20 November 2019 – Washington DC – Efforts to eliminate river blindness, a debilitating disease affecting millions in Africa, will be hampered by another parasitic infection known as Loiasis, or ‘African eye worm,’ according to a study published in Clinical Infectious Diseases.

While the World Health Organization (WHO) has targeted the elimination of river blindness in most African countries by 2025, researchers from Erasmus MC, University Medical Center Rotterdam in the Netherlands and the Drugs for Neglected Diseases initiative (DNDi) have estimated that over 4 million people in West and Central Africa will still be infected with the disease in 2025 in areas where African eye worm is endemic.

In their modelling study, the researchers also found that 90% of these people will live in areas currently not covered by treatment programmes for river blindness, posing a major challenge to the elimination of this disease.

River blindness is transmitted by the bite of an infected blackfly and causes severe itching, skin lesions, and eventually blindness. African eye worm gets its name from its most infamous tell-tale sign: the visible passing of the Loa loa worm through the eye. Individuals with a very high amount of Loa loa larvae (microfilariae) in the blood are at risk of life-threatening complications if they receive ivermectin, a drug for river blindness.

Mass drug administration programmes of ivermectin need to be repeated for 10-12 years or more, as these treatments only kill the juvenile filarial worms that cause river blindness, and adult worms can live more than 10 years in the human body. Because of the risk of dangerous side effects, ivermectin cannot be safely used in areas co-endemic for river blindness and African eye worm and mass drug administration programmes have not been started in some of these areas.

‘The current approach to preventing river blindness based on mass drug administration of ivermectin has been extraordinarily successful,’ says Sabine Specht, Head of Filarial Clinical Programme at DNDi. ‘But this study supports that alternative treatment strategies will be needed if we want to eliminate the disease, including the development of entirely new tools that offer a rapid and safe cure for river blindness.’

DNDi aims to develop a safe, effective, affordable, and field-adapted ‘macrofilaricidal’ drug that can kill adult filarial worms and be used for individual patient treatment and to support the elimination of river blindness in Africa in areas that are difficult to treat.

###

About DNDi

The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit research and development organization working to deliver new treatments for neglected diseases – notably leishmaniasis, sleeping sickness, Chagas disease, specific filarial infections, and mycetoma – as well as treatments for neglected patients, particularly those living with paediatric HIV and hepatitis C. Since its inception in 2003, DNDi and its partners have already delivered eight innovative treatments to improve the quality of life and health of patients. DNDi.org”>http://www.DNDi.org

Media contacts

DNDi North America, attending ASTMH 2019

Ilan Moss

+1 646 266 5216

DNDi.org”>imoss@DNDi.org

DNDi Switzerland

Moyette Gibbons

+41 22 555 19 29

+41 79 940 9017

DNDi.org”>mgibbons@DNDi.org

Media Contact
Moyette Gibbons
[email protected]
41-799-409-017

Tags: Clinical TrialsDisease in the Developing WorldHealth CareHealth Care Systems/ServicesInfectious/Emerging DiseasesMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Auditory Change Processing Markers Unusual in Autism

October 23, 2025

Innovative Center Pioneers Brighter Future for Trauma Survivors

October 23, 2025

Exploring Vicarious Trauma in Hospice Nurses

October 23, 2025

Assessing Muscularity Overvaluation and Eating Disorder Risks

October 23, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1277 shares
    Share 510 Tweet 319
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    308 shares
    Share 123 Tweet 77
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    167 shares
    Share 67 Tweet 42
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    132 shares
    Share 53 Tweet 33

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Auditory Change Processing Markers Unusual in Autism

Innovative Center Pioneers Brighter Future for Trauma Survivors

Exploring Vicarious Trauma in Hospice Nurses

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 66 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.